135 related articles for article (PubMed ID: 25668009)
1. MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.
Walter RF; Mairinger FD; Ting S; Vollbrecht C; Mairinger T; Theegarten D; Christoph DC; Schmid KW; Wohlschlaeger J
Br J Cancer; 2015 Mar; 112(5):883-90. PubMed ID: 25668009
[TBL] [Abstract][Full Text] [Related]
2. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
3. Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer.
Inoue K; Fry EA
Int J Cancer; 2016 Jul; 139(1):33-41. PubMed ID: 26802432
[TBL] [Abstract][Full Text] [Related]
4. High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.
Carr-Wilkinson J; O'Toole K; Wood KM; Challen CC; Baker AG; Board JR; Evans L; Cole M; Cheung NK; Boos J; Köhler G; Leuschner I; Pearson AD; Lunec J; Tweddle DA
Clin Cancer Res; 2010 Feb; 16(4):1108-18. PubMed ID: 20145180
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition.
Paternot S; Raspé E; Meiller C; Tarabichi M; Assié JB; Libert F; Remmelink M; Bisteau X; Pauwels P; Blum Y; Le Stang N; Tabone-Eglinger S; Galateau-Sallé F; Blanquart C; Van Meerbeeck JP; Berghmans T; Jean D; Roger PP
Mol Oncol; 2024 Apr; 18(4):866-894. PubMed ID: 36453028
[TBL] [Abstract][Full Text] [Related]
6. p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma.
Muramatsu N; Ichikawa M; Katagiri T; Taguchi Y; Hatanaka T; Okuda T; Okamoto H
Gene Ther; 2024 Mar; 31(3-4):119-127. PubMed ID: 37833562
[TBL] [Abstract][Full Text] [Related]
7. CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.
Roncella S; Laurent S; Fontana V; Ferro P; Franceschini MC; Salvi S; Varesano S; Boccardo S; Vigani A; Morabito A; Canessa PA; Giannoni U; Rosenberg I; Valentino A; Fedeli F; Merlo DF; Ceppi M; Riggio S; Romani M; Saverino D; Poggi A; Pistillo MP
Cancer Immunol Immunother; 2016 Aug; 65(8):909-17. PubMed ID: 27207606
[TBL] [Abstract][Full Text] [Related]
8. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target.
Crispi S; Calogero RA; Santini M; Mellone P; Vincenzi B; Citro G; Vicidomini G; Fasano S; Meccariello R; Cobellis G; Menegozzo S; Pierantoni R; Facciolo F; Baldi A; Menegozzo M
PLoS One; 2009 Sep; 4(9):e7016. PubMed ID: 19753302
[TBL] [Abstract][Full Text] [Related]
9. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials.
Kotova S; Wong RM; Cameron RB
Cancer Manag Res; 2015; 7():51-63. PubMed ID: 25670913
[TBL] [Abstract][Full Text] [Related]
10. microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.
Walter RF; Vollbrecht C; Werner R; Wohlschlaeger J; Christoph DC; Schmid KW; Mairinger FD
Oncotarget; 2016 Apr; 7(14):18713-21. PubMed ID: 26918730
[TBL] [Abstract][Full Text] [Related]
11. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial.
Arnold DT; Hooper CE; Morley A; White P; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Rahman NM; De Winton E; Clive A; Masani V; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
Br J Cancer; 2015 Mar; 112(7):1183-9. PubMed ID: 25756395
[TBL] [Abstract][Full Text] [Related]
12. Expression status of candidate genes in mesothelioma tissues and cell lines.
Melaiu O; Melissari E; Mutti L; Bracci E; De Santi C; Iofrida C; Di Russo M; Cristaudo A; Bonotti A; Cipollini M; Garritano SI; Foddis R; Lucchi M; Pellegrini S; Gemignani F; Landi S
Mutat Res; 2015 Jan; 771():6-12. PubMed ID: 25771974
[TBL] [Abstract][Full Text] [Related]
13. The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication.
Hooper CE; Lyburn ID; Searle J; Darby M; Hall T; Hall D; Morley A; White P; Rahman NM; De Winton E; Clive A; Masani V; Arnold DT; Dangoor A; Guglani S; Jankowska P; Lowndes SA; Harvey JE; Braybrooke JP; Maskell NA
Br J Cancer; 2015 Mar; 112(7):1175-82. PubMed ID: 25756396
[TBL] [Abstract][Full Text] [Related]
14. Changing pattern in malignant mesothelioma survival.
Faig J; Howard S; Levine EA; Casselman G; Hesdorffer M; Ohar JA
Transl Oncol; 2015 Feb; 8(1):35-9. PubMed ID: 25749175
[TBL] [Abstract][Full Text] [Related]
15. Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma.
Kaya H; Demir M; Taylan M; Sezgi C; Tanrikulu AC; Yilmaz S; Bayram M; Kaplan I; Senyigit A
Asian Pac J Cancer Prev; 2015; 16(4):1403-7. PubMed ID: 25743806
[TBL] [Abstract][Full Text] [Related]
16. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
Røe OD; Stella GM
Eur Respir Rev; 2015 Mar; 24(135):115-31. PubMed ID: 25726562
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53.
Walter RFH; Werner R; Wessolly M; Mairinger E; Borchert S; Schmeller J; Kollmeier J; Mairinger T; Hager T; Bankfalvi A; Christoph DC; Eberhardt WEE; Plönes T; Aigner C; Schmid KW; Wohlschlaeger J; Mairinger FD
J Oncol; 2018; 2018():1986982. PubMed ID: 30112000
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell cytoplasmic metallothionein expression associates with differential tumor immunogenicity and prognostic outcome in high-grade serous ovarian carcinoma.
Mairinger E; Wessolly M; Buderath P; Borchert S; Henrich L; Mach P; Steinborn J; Kimming R; Jasani B; Schmid KW; Bankfalvi A; Mairinger FD
Front Oncol; 2023; 13():1252700. PubMed ID: 38023247
[TBL] [Abstract][Full Text] [Related]
19. Double Empirical Bayes Testing.
Tansey W; Wang Y; Rabadan R; Blei DM
Int Stat Rev; 2020 Dec; 88(Suppl 1):S91-S113. PubMed ID: 35356801
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma: an update.
Hajj GNM; Cavarson CH; Pinto CAL; Venturi G; Navarro JR; Lima VCC
J Bras Pneumol; 2021; 47(6):e20210129. PubMed ID: 34909922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
